|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:CureVac_AG
gptkb:Apexigen,_Inc.
|
|
gptkbp:CEO
|
gptkb:Roger_Tung
|
|
gptkbp:clinicalTrials
|
Phase 2
Phase 3
Phase 3 trials
biopharmaceutical company
Phase 1 trials
Phase 2 trials
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:Johns_Hopkins_University
gptkb:Massachusetts_Institute_of_Technology
gptkb:University_of_Pennsylvania
multiple pharmaceutical companies
|
|
gptkbp:employeeCount
|
51-200
|
|
gptkbp:financialPerformance
|
NASDAQ_listed
|
|
gptkbp:financials
|
venture capital
public offering
|
|
gptkbp:focus
|
drug development
|
|
gptkbp:founded
|
2006
|
|
gptkbp:founder
|
gptkb:Roger_Tung
|
|
gptkbp:headquarters
|
gptkb:Lexington,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Concert Pharmaceuticals
|
|
gptkbp:investmentFocus
|
gptkb:New_Enterprise_Associates
gptkb:Frazier_Healthcare_Partners
OrbiMed Advisors
|
|
gptkbp:leadership
|
experienced management team
|
|
gptkbp:market
|
approximately $200 million
|
|
gptkbp:mission
|
improve patient outcomes
|
|
gptkbp:notableFeature
|
CNP-104
CNP-501
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:patentCitation
|
multiple drug candidates
|
|
gptkbp:publications
|
numerous peer-reviewed articles
|
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
EMA
|
|
gptkbp:research_areas
|
oncology
cardiovascular diseases
infectious diseases
|
|
gptkbp:research_focus
|
autoimmune diseases
central nervous system disorders
metabolic diseases
|
|
gptkbp:revenue
|
$10 million
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
CNCE
|
|
gptkbp:tributaryOf
|
CNP-104 for autoimmune diseases
CNP-301 for CNS disorders
CNP-501 for organ transplant
|
|
gptkbp:vision
|
transforming medicine through innovation.
|
|
gptkbp:website
|
www.concertpharma.com
|